Skip to main content
26/04/2023 - 15:10

Chimeric gets green light for multi-site US cancer trial

26/04/2023 - 15:10

Bookmark

Save articles for future reference.

ASX-listed cell therapy company Chimeric Therapeutics has received ethics approval to start a multi-site phase 1B clinical trial of the company’s CHM 1101 cell treatment for patients with glioblastoma. Management says the new development will see a two-part clinical study enrolling patients across multiple clinical trial sites in the United States.

X